Launched in 2019, Dewpoint is based on the work of Anthony Hyman, a researcher who was part of the team that discovered biomolecular condensates. Shape-shifting blobs, these condensates form inside cells and can contain proteins and other molecules. Researchers have started to explore how condensates affect chemical reactions in the cell and potentially play a role in disease.
Dewpoint is one of several biotechnology companies attempting to create new treatments through studying condensates. While Dewpoint is working across several different therapeutic areas, its metabolic research is what drew the attention of Novo, the pharma company that sells the in-demand diabetes drug Ozempic.
The partnership will focus on the discovery of small molecule drugs to treat insulin resistance and diabetic complications. The companies claim that undoing the dysregulation of condensates could help forestall development of insulin resistance, which is a key factor in Type 2 diabetes. READ MORE
by Delilah Alvarado
Source: biopharmadive.com
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.